Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 13 studies | 29% ± 10% | |
classical monocyte | 12 studies | 25% ± 8% | |
pericyte | 9 studies | 43% ± 17% | |
smooth muscle cell | 9 studies | 36% ± 11% | |
macrophage | 6 studies | 28% ± 7% | |
endothelial cell | 6 studies | 24% ± 5% | |
neutrophil | 6 studies | 22% ± 4% | |
non-classical monocyte | 6 studies | 23% ± 5% | |
natural killer cell | 5 studies | 23% ± 11% | |
conventional dendritic cell | 4 studies | 27% ± 9% | |
epithelial cell | 4 studies | 32% ± 21% | |
endothelial cell of vascular tree | 4 studies | 29% ± 9% | |
dendritic cell | 3 studies | 36% ± 4% | |
monocyte | 3 studies | 38% ± 15% | |
endothelial cell of lymphatic vessel | 3 studies | 26% ± 6% | |
myeloid cell | 3 studies | 29% ± 2% | |
ciliated cell | 3 studies | 34% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 99% | 6512.40 | 575 / 578 | 100% | 62.58 | 1152 / 1155 |
prostate | 99% | 5962.95 | 242 / 245 | 100% | 95.30 | 502 / 502 |
uterus | 98% | 6546.93 | 166 / 170 | 99% | 65.08 | 455 / 459 |
ovary | 99% | 8247.20 | 179 / 180 | 97% | 33.33 | 416 / 430 |
breast | 100% | 7873.48 | 459 / 459 | 92% | 42.81 | 1034 / 1118 |
liver | 92% | 5805.79 | 209 / 226 | 99% | 59.47 | 400 / 406 |
bladder | 95% | 4315.48 | 20 / 21 | 95% | 46.16 | 477 / 504 |
skin | 99% | 5508.70 | 1787 / 1809 | 91% | 30.00 | 428 / 472 |
intestine | 87% | 3916.57 | 844 / 966 | 98% | 40.26 | 519 / 527 |
esophagus | 84% | 2963.49 | 1217 / 1445 | 99% | 56.18 | 181 / 183 |
thymus | 88% | 2661.22 | 572 / 653 | 91% | 30.74 | 551 / 605 |
kidney | 82% | 2948.15 | 73 / 89 | 94% | 66.11 | 846 / 901 |
stomach | 62% | 3282.28 | 221 / 359 | 99% | 37.51 | 284 / 286 |
adrenal gland | 81% | 3604.01 | 210 / 258 | 64% | 26.75 | 147 / 230 |
pancreas | 34% | 724.67 | 111 / 328 | 99% | 59.33 | 176 / 178 |
brain | 24% | 548.83 | 634 / 2642 | 99% | 46.69 | 700 / 705 |
tonsil | 0% | 0 | 0 / 0 | 100% | 63.10 | 45 / 45 |
adipose | 100% | 10731.75 | 1200 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 8642.68 | 1321 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 47.28 | 75 / 80 |
muscle | 93% | 7215.93 | 748 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 43.36 | 27 / 29 |
peripheral blood | 85% | 9882.36 | 787 / 929 | 0% | 0 | 0 / 0 |
heart | 82% | 3086.14 | 709 / 861 | 0% | 0 | 0 / 0 |
spleen | 82% | 1735.89 | 197 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0001779 | Biological process | natural killer cell differentiation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0071353 | Biological process | cellular response to interleukin-4 |
GO_0007623 | Biological process | circadian rhythm |
GO_0006955 | Biological process | immune response |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0042802 | Molecular function | identical protein binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NFIL3 |
Protein name | Nuclear factor interleukin-3-regulated protein (E4 promoter-binding protein 4) (Interleukin-3 promoter transcriptional activator) (Interleukin-3-binding protein 1) (Transcriptional activator NF-IL3A) Nuclear factor interleukin-3-regulated protein |
Synonyms | IL3BP1 E4BP4 |
Description | FUNCTION: Acts as a transcriptional regulator that recognizes and binds to the sequence 5'-[GA]TTA[CT]GTAA[CT]-3', a sequence present in many cellular and viral promoters. Represses transcription from promoters with activating transcription factor (ATF) sites. Represses promoter activity in osteoblasts (By similarity). Represses transcriptional activity of PER1 (By similarity). Represses transcriptional activity of PER2 via the B-site on the promoter (By similarity). Activates transcription from the interleukin-3 promoter in T-cells. Competes for the same consensus-binding site with PAR DNA-binding factors (DBP, HLF and TEF) (By similarity). Component of the circadian clock that acts as a negative regulator for the circadian expression of PER2 oscillation in the cell-autonomous core clock (By similarity). Protects pro-B cells from programmed cell death (By similarity). Represses the transcription of CYP2A5 (By similarity). Positively regulates the expression and activity of CES2 by antagonizing the repressive action of NR1D1 on CES2 (By similarity). Required for the development of natural killer cell precursors (By similarity). . FUNCTION: Acts as a transcriptional regulator that recognizes and binds to the sequence 5'-[GA]TTA[CT]GTAA[CT]-3', a sequence present in many cellular and viral promoters. Represses transcription from promoters with activating transcription factor (ATF) sites. Represses promoter activity in osteoblasts. Represses transcriptional activity of PER1. Represses transcriptional activity of PER2 via the B-site on the promoter. Activates transcription from the interleukin-3 promoter in T-cells. Competes for the same consensus-binding site with PAR DNA-binding factors (DBP, HLF and TEF). Component of the circadian clock that acts as a negative regulator for the circadian expression of PER2 oscillation in the cell-autonomous core clock. Protects pro-B cells from programmed cell death. . |
Accessions | ENST00000297689.4 D9IVD5 Q16649 |